

## Prof. MURAT AKOVA

### Personal Information

Office Phone: [+90 312 311 1271](tel:+903123111271)

Fax Phone: [+90 312 310 4179](tel:+903123104179)

Email: [makova@hacettepe.edu.tr](mailto:makova@hacettepe.edu.tr)

Web: <https://avesis.hacettepe.edu.tr/makova>

Address: Hacettepe Tıp Fakültesi, Erişkin Enfeksiyon Hastalıkları, 9 No.lu giriş, 1. kat Sıhhiye 06100 Ankara

### International Researcher IDs

ORCID: 0000-0002-6904-9473

ScopusID: 55905807500

Yoksis Researcher ID: 6476

### Education Information

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1984 - 1989

### Research Areas

Medicine

### Academic Titles / Tasks

Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 1998 - Continues

### Academic and Administrative Experience

Hacettepe Üniversitesi, Tıp Fakültesi, 2000 - 2006

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Scientific misconduct in infectious diseases-European Society of Clinical Microbiology and Infectious Diseases survey**  
Tau N., AKOVA M., Barac A., Nasim A., Righi E., Yahav D.  
CLINICAL MICROBIOLOGY AND INFECTION, no.11, 2024 (SCI-Expanded)
- II. **The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy: Another Opportunity for Stewardship?**  
Aslan A. T., AKOVA M., Kontoyiannis D. P.  
CLINICAL INFECTIOUS DISEASES, 2024 (SCI-Expanded)
- III. **Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies**  
Aslan A. T., AKOVA M.  
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024 (SCI-Expanded)

- IV. **Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged  $\geq 75$  years (EU-COVAT-1-AGED Part B)**  
Stemler J, Yeghiazaryan L, Stephan C, Mohn K. G., Carcas-Sansuan A., Rodriguez E. R., Molto J, Mitxeltorena I. V., Welte T, Zablockiene B., et al.  
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024 (SCI-Expanded)
- V. **Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study**  
Salmanton-Garcia J, Cornely O. A., Stemler J, Barac A, Steinmann J, Sivakova A, AKALIN E. H., Arikan-Akdaglii S, Loughlinj L., Toscano C., et al.  
JOURNAL OF INFECTION, no.3, 2024 (SCI-Expanded)
- VI. **An Institutional Febrile Neutropenia Protocol Improved the Antibacterial Treatment and Encouraged the Development of a Computerized Clinical Decision Support System**  
TAŞ Z., METAN G., TELLİ DİZMAN G., Yavuz E., DİZDAR Ö., BÜYÜKAŞIK Y., UZUN Ö., AKOVA M.  
ANTIBIOTICS-BASEL, no.9, 2024 (SCI-Expanded)
- VII. **Beyond conventional dosing: tailoring antimicrobial regimens for cachexia**  
KILINÇ E. E., BAYRAKTAR ALKAN İ., KARA E., DEMİRKAN S. K., AKOVA M.  
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024 (SCI-Expanded)
- VIII. **Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study**  
Zhou H., Buetti N., Perez-Galera S., Bravo-Ferrer J., Gutierrez-Gutierrez B., Paniagua-Garcia M., Jan F., Sauser J., Kostyanov T., Canton R., et al.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024 (SCI-Expanded)
- IX. **Hospital-acquired bloodstream infections in critically ill cirrhotic patients: a post-hoc analysis of the EUROBACT-2 international cohort study**  
Wozniak H., Tabah A., Barbier F., Ruckly S., Loiodice A., AKOVA M., Leone M., Morris A. C., Bassetti M., Arvaniti K., et al.  
ANNALS OF INTENSIVE CARE, no.1, 2024 (SCI-Expanded)
- X. **Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM**  
Bassetti M., Giacobbe D. R., Agvald-Ohman C., AKOVA M., Alastruey-Izquierdo A., ARIKAN AKDAĞLI S., Azoulay E., Blot S., Cornely O. A., Cuenca-Estrella M., et al.  
Intensive Care Medicine, vol.50, no.4, pp.502-515, 2024 (SCI-Expanded)
- XI. ***Pseudomonas aeruginosa* Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy**  
Royo-Cebrecos C., Laporte-Amargos J., Pena M., Ruiz-Camps I., Garcia-Vidal C., Abdala E., Oltolini C., AKOVA M., Montejo M., Mikulska M., et al.  
MICROORGANISMS, no.4, 2024 (SCI-Expanded)
- XII. **Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)**  
Paniagua-García M., Bravo-Ferrer J. M., Pérez-Galera S., Kostyanov T., de Kraker M. E. A., Feifel J., Palacios-Baena Z. R., Schotsman J., Cantón R., Daikos G. L., et al.  
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, vol.30, no.2, pp.223-230, 2024 (SCI-Expanded)
- XIII. **The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections**  
Buetti N., Tabah A., Setti N., Ruckly S., Barbier F., AKOVA M., ASLAN A. T., Leone M., Bassetti M., Morris A. C., et al.  
Intensive Care Medicine, 2024 (SCI-Expanded)
- XIV. **Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients**  
Teh B. W., Mikulska M., Averbuch D., de la Camara R., Hirsch H. H., AKOVA M., Ostrosky-Zeichner L., Baddley J. W., Tan B. H., Mularoni A., et al.

The Lancet Infectious Diseases, vol.24, no.1, 2024 (SCI-Expanded)

- XV. **Human memory T cell dynamics after aluminum-adsorbed inactivated whole-virion SARS-CoV-2 vaccination**  
Tavukcuoglu E., Yanik H., Parveen M., Uluturk S., DURUSU TANRIÖVER M., İNKAYA A. Ç., AKOVA M., ÜNAL S., ESENDAĞLI G.  
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- XVI. **The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium**  
Poulimeneas D., Koniordou M., Kousi D., Merakou C., Kopsidas I., Tsopele G. C., Argyropoulos C. D., Themistocleous S. C., Shiamakkides G., Constantinou M., et al.  
VACCINES, no.12, 2023 (SCI-Expanded)
- XVII. **Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults  $\geq 75$  years (EU-COVAT-1)**  
Neuhann J. M., Stemler J., Carcas A. J., Frías-Iniesta J., AKOVA M., Bethe U., Heringer S., Salmanton-García J., Tischmann L., Zarrouk M., et al.  
Vaccine, vol.41, no.48, pp.7166-7175, 2023 (SCI-Expanded)
- XVIII. **Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study**  
ASLAN A. T., Tabah A., KÖYLÜ B., Kalem A. K., AKSOY F., Erol Ç., KARAALI R., TUNAY B., Guzeldağ S., Batirel A., et al.  
The Journal of antimicrobial chemotherapy, vol.78, no.7, pp.1757-1768, 2023 (SCI-Expanded)
- XIX. **VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe**  
Salmanton-García J., Wipfler P., Valle-Simón P., Merakou C., Kopsidas I., Bethe U., Steinbach A., Spivak O., Součková L., Mendonça M. A., et al.  
Vaccine, vol.41, no.26, pp.3915-3922, 2023 (SCI-Expanded)
- XX. **Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study**  
Hoeningl M., Salmanton-García J., Egger M., Gangneux J., Bicanic T., ARIKAN AKDAĞLI S., Alastruey-Izquierdo A., Klimko N., Barac A., Özenci V., et al.  
The Lancet Infectious Diseases, vol.23, no.6, pp.751-761, 2023 (SCI-Expanded)
- XXI. **Duration of antibiotic treatment and timing of oral switching for bloodstream infections: a survey on the practices of infectious diseases and intensive care physicians**  
İsler B., Aslan A. T., BENLİ B. S., Paterson D. L., Daneman N., Fowler R., AKOVA M.  
International Journal of Antimicrobial Agents, vol.61, no.6, 2023 (SCI-Expanded)
- XXII. **Q Fever Endocarditis-Associated Immune Complex-Mediated Proliferative Glomerulonephritis: Fourth Case from Türkiye Q Ateşi Endokarditi İlişkili İmmün Kompleks Aracılı Proliferatif Glomerülonefrit: Türkiye'den Dördüncü Olgu**  
İsmayilov R., Acar B. N., KAPAR B., ERDUT A., ÖZDEDE M., Sağlam A., AKOVA M.  
Mikrobiyoloji bulteni, vol.57, no.2, pp.293-300, 2023 (SCI-Expanded)
- XXIII. **Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)**  
Pérez-Galera S., Bravo-Ferrer J. M., Paniagua M., Kostyanov T., de Kraker M. E., Feifel J., Sojo-Dorado J., Schotsman J., Cantón R., Daikos G. L., et al.  
eClinicalMedicine, vol.57, 2023 (SCI-Expanded)
- XXIV. **Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicentre observational study (CardINE Study)**  
Pascale R., Toschi A., Aslan A. T., Massaro G., Maccaro A., Fabbricatore D., Dell'Aquila A., Ripa M., Işık M. E., Kızmaz Y. U., et al.  
International Journal of Antimicrobial Agents, vol.61, no.3, 2023 (SCI-Expanded)
- XXV. **Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EURO-BACT-2 international cohort study**  
Tabah A., Buetti N., Staiquily Q., Ruckly S., AKOVA M., ASLAN A. T., Leone M., Conway Morris A., Bassetti M., Arvaniti

K., et al.

Intensive care medicine, vol.49, no.2, pp.178-190, 2023 (SCI-Expanded)

- XXVI. **Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study**  
ŞAHİN T. K., ERUL E., AKSUN M. S., SÖNMEZER M. Ç., ÜNAL S., AKOVA M.  
Vaccines, vol.11, no.1, 2023 (SCI-Expanded)
- XXVII. **Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit**  
Argyropoulos C. D., Leckler J., Salmanton-García J., Constantinou M., Alexandrou A., Themistocleous S., Noula E., Shiamakkides G., Nearchou A., Stewart F. A., et al.  
JMIR Public Health and Surveillance, vol.9, 2023 (SCI-Expanded)
- XXVIII. **Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints**  
Isler B., Vatansever C., Özer B., ÇINAR G., ASLAN A. T., Falconer C., Bauer M. J., Forde B., Şimşek F., Tülek N., et al.  
Infectious Diseases, vol.55, no.9, pp.607-613, 2023 (SCI-Expanded)
- XXIX. **Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia**  
Bergeron A., Mikulska M., De Greef J., Bondeelle L., Franquet T., Herrmann J., Lange C., Spriet I., AKOVA M., Donnelly J. P., et al.  
The Lancet Infectious Diseases, vol.22, no.12, 2022 (SCI-Expanded)
- XXX. **Foreword**  
Pagliuca A., AKOVA M.  
The Journal of antimicrobial chemotherapy, vol.77, no.2, 2022 (SCI-Expanded)
- XXXI. **Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections**  
Isler B., Aslan A. T., AKOVA M., Harris P., Paterson D. L.  
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, vol.20, no.11, pp.1389-1400, 2022 (SCI-Expanded)
- XXXII. **Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors**  
Royo-Cebrecos C., Laporte-Amargos J., Pena M., Ruiz-Camps I., Puerta-Alcalde P., Abdala E., Oltolini C., AKOVA M., Montejo M., Mikulska M., et al.  
PATHOGENS, vol.11, no.10, 2022 (SCI-Expanded)
- XXXIII. **Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates**  
Isler B., Vatansever C., Ozer B., ÇINAR G., ASLAN A. T., Stewart A., Simos P., Falconer C., Bauer M. J., Forde B., et al.  
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol.104, no.1, 2022 (SCI-Expanded)
- XXXIV. **Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022**  
Canton R., AKOVA M., Langfeld K., Torumkuney D.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.77, pp.2-9, 2022 (SCI-Expanded)
- XXXV. **Piperacillin-Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?**  
Aslan A. T., Akova M.  
HEALTHCARE, vol.10, no.8, 2022 (SCI-Expanded)
- XXXVI. **VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment**  
Salmanton-García J., Stewart F. A., Heringer S., Koniordou M., Álvarez-Barco E., Argyropoulos C. D., Themistocleous S. C., Valle-Simón P., Spivak O., Součková L., et al.  
Vaccine, vol.40, no.31, pp.4090-4097, 2022 (SCI-Expanded)
- XXXVII. **Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey**  
SÖNMEZER M. Ç., TELLİ DİZMAN G., Erul E., ŞAHİN T. K., SARICAÖĞLU T., Alp A., DURUSU TANRIÖVER M., UZUN Ö,

ÜNAL S., AKOVA M.

VACCINES, vol.10, no.7, 2022 (SCI-Expanded)

- XXXVIII. **Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?**  
Metan G., UZUN Ö., Dizman G., SÖNMEZER M. Ç., İNKAYA A. Ç., HAZIROLAN G., AKOVA M., Unal S.  
Infection control and hospital epidemiology, vol.43, no.6, pp.802-804, 2022 (SCI-Expanded)
- XXXIX. **COVID-19 vaccine booster strategy: striving for best practice**  
DURUSU TANRIÖVER M., AKOVA M.  
LANCET GLOBAL HEALTH, vol.10, no.6, 2022 (SCI-Expanded)
- XL. **Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting**  
Isler B., Ozer B., ÇINAR G., ASLAN A. T., Vatanserver C., Falconer C., Dolapci I., Simsek F., TÜLEK N., Demirkaya H., et al.  
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.41, no.5, pp.841-847, 2022 (SCI-Expanded)
- XLI. **Barriers Against Hepatitis B Vaccination in High-Risk Adults: A Cross-Sectional Study**  
ASLAN A. T., ŞAŞMAZER B., AYAR Y., Duran Z. C., AKOVA M.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.5, pp.427-436, 2022 (SCI-Expanded)
- XLII. **Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia**  
Albasanz-Puig A., Dura-Miralles X., Laporte-Amargos J., Mussetti A., Ruiz-Camps I., Puerta-Alcalde P., Abdala E., Oltolini C., AKOVA M., Miguel Montejo J., et al.  
MICROORGANISMS, vol.10, no.4, 2022 (SCI-Expanded)
- XLIII. **The ESCMID ethics advisory committee (EEAC): purpose and challenges Comment**  
Righi E., Yahav D., AKOVA M., Nasim A., Barac A.  
CLINICAL MICROBIOLOGY AND INFECTION, vol.28, no.4, pp.470-471, 2022 (SCI-Expanded)
- XLIV. **A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.**  
Aslan A. T., Kirbaş E., Sancak B., Tanrıverdi E. S., Otlu B., Gürsoy N. C., Yılmaz Y. A., Tozluyurt A., Liste Ü., Bıçakcığıl A., et al.  
International journal of antimicrobial agents, vol.59, pp.106554, 2022 (SCI-Expanded)
- XLV. **The Role of Colistin in the Era of New beta-Lactam/beta-Lactamase Inhibitor Combinations**  
Aslan A. T., AKOVA M.  
ANTIBIOTICS-BASEL, vol.11, no.2, 2022 (SCI-Expanded)
- XLVI. **CoronaVac efficacy data from Turkey – Authors' reply**  
DURUSU TANRIÖVER M., Doğanay H. L., ÜNAL S., AKOVA M.  
The Lancet, vol.398, no.10314, pp.1874, 2021 (SCI-Expanded)
- XLVII. **Untitled reply**  
Tanrıover M. D., Doganay H. L., ÜNAL S., AKOVA M.  
LANCET, vol.398, no.10314, pp.1874, 2021 (SCI-Expanded)
- XLVIII. **Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital**  
KARA E., METAN G., Bayraktar-Ekincioglu A., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., DEMİRKAZIK F., AKOVA M., ÜNAL S., UZUN Ö.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.65, no.9, 2021 (SCI-Expanded)
- XLIX. **Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury**  
ASLAN A. T., Pashayev T., DAĞ O., AKOVA M.  
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.40, no.9, pp.1953-1961, 2021 (SCI-Expanded)
- L. **Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study**

Quan J., Dai H., Liao W., Zhao D., Shi Q., Zhang L., Shi K., AKOVA M., Yu Y.

JOURNAL OF INFECTION, vol.83, no.2, pp.175-181, 2021 (SCI-Expanded)

- LI. **Expect the unexpected: fungemia caused by uncommon *Candida* species in a Turkish University Hospital**  
Özyavuz Alp Ş., Gülmez Kıvanç D., Kardaş R. C., Karahan G., Taş Z., Gürsoy G., Ayaz Ceylan Ç. M., Arıkan Akdağlı S., Akova M.  
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.40, no.7, pp.1539-1545, 2021 (SCI-Expanded)
- LII. **Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey**  
DURUSU TANRIÖVER M., Doganay H. L., AKOVA M., Guner H. R., Azap A., AKHAN S., Kose S., Erdinc F. S., AKALIN E. H., TABAK Ö. F., et al.  
LANCET, vol.398, no.10296, pp.213-222, 2021 (SCI-Expanded)
- LIII. **A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial**  
AKOVA M., ÜNAL S.  
TRIALS, vol.22, no.1, 2021 (SCI-Expanded)
- LIV. **Persistent dermal lesions in a patient with previous history of visceral leishmaniasis**  
Jaiteh M. B., İNKAYA A. Ç., ÜNER A., ELÇİN G., ERGÜVEN S., KURTULAN O., Harxhi A., AKOVA M.  
PARASITOLOGY INTERNATIONAL, vol.80, 2021 (SCI-Expanded)
- LV. **Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study**  
De Bus L., Depuydt P., Steen J., Dhaese S., De Smet K., Tabah A., AKOVA M., Cotta M. O., De Pascale G., Dimopoulos G., et al.  
INTENSIVE CARE MEDICINE, vol.46, no.7, pp.1404-1417, 2020 (SCI-Expanded)
- LVI. **Fungal infections of the skin and soft tissue**  
DOĞAN GÜNAYDIN S., ARIKAN AKDAĞLI S., AKOVA M.  
CURRENT OPINION IN INFECTIOUS DISEASES, vol.33, no.2, pp.130-136, 2020 (SCI-Expanded)
- LVII. **Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network**  
Rello J., Sarda C., Mokart D., Arvaniti K., AKOVA M., Tabah A., Azoulay E., Rabbat A., Darmon M., Klouche K., et al.  
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.39, no.2, pp.385-392, 2020 (SCI-Expanded)
- LVIII. **Understanding resistance in *Pseudomonas***  
Dimopoulos G., AKOVA M., Rello J., Poulakou G.  
INTENSIVE CARE MEDICINE, vol.46, no.2, pp.350-352, 2020 (SCI-Expanded)
- LIX. **Ultrastructural evaluation of urine alkalization versus hydration on colistin-induced nephrotoxicity**  
Korucu B., Unal I., Pekcan M., İNKAYA A. Ç., Yeter H. H., ÇETİNKAYA M. A., KAYMAZ F. F., ÜNAL S., AKOVA M., ERDEM Y.  
Human and Experimental Toxicology, vol.38, no.12, pp.1366-1377, 2019 (SCI-Expanded)
- LX. **Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium**  
Cornely O. A., Alastruey-Izquierdo A., Arenz D., Chen S. C. A., Dannaoui E., Hochhegger B., Hoenigl M., Jensen H. E., Lagrou K., Lewis R. E., et al.  
LANCET INFECTIOUS DISEASES, vol.19, no.12, 2019 (SCI-Expanded)
- LXI. **Extended spectrum beta-lactamase producing enterobacteriaceae: carbapenem sparing options**  
ASLAN A. T., AKOVA M.  
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2019 (SCI-Expanded)

- LXII. Dual Role of gnaA in Antibiotic Resistance and Virulence in Acinetobacter baumannii**  
 Xu Q, Chen T, Yan B, Zhang L, Pi B, Yang Y, Zhang L, Zhou Z, Ji S, Leptihn S, et al.  
 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.63, no.10, 2019 (SCI-Expanded)
- LXIII. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study**  
 Albasanz-Puig A, Gudiol C, Parody R, Tebe C, AKOVA M, Araos R, Bote A, Brunel A, Calik S, Drgona L, et al.  
 BMJ OPEN, vol.9, no.5, 2019 (SCI-Expanded)
- LXIV. Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project**  
 Bassetti M, Scudeller L, Giacobbe D. R., Lamoth F., Righi E., Zuccaro V., Grecchi C., Rebuffi C., AKOVA M., Alastruey-Izquierdo A., et al.  
 MYCOSES, vol.62, no.4, pp.310-319, 2019 (SCI-Expanded)
- LXV. Immigrants as donors and transplant recipients: specific considerations**  
 Poulakou G., Len O., AKOVA M.  
 INTENSIVE CARE MEDICINE, vol.45, no.3, pp.401-403, 2019 (SCI-Expanded)
- LXVI. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae**  
 Scheuerman O, Schechner V, Carmeli Y, Gutierrez-Gutierrez B, Calbo E, Almirante B, Viale P, Oliver A, Ruiz-Garbajosa P, Gasch O, et al.  
 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, vol.39, no.6, pp.660-667, 2018 (SCI-Expanded)
- LXVII. Neuroinvasive Listeriosis Could Petechial Hemorrhages be a Diagnostic Clue?**  
 Diker S, OKAR S, Mehdikhanova L, ARSAVA E. M., KURNE A., CEVIK I. U., AKYON Y., ALP Ş., INKAYA C., AKOVA M., et al.  
 NEUROLOGIST, vol.23, no.3, pp.86-91, 2018 (SCI-Expanded)
- LXVIII. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance**  
 De Waele J. J., AKOVA M., Antonelli M., Canton R., Carlet J., De Backer D., Dimopoulos G., Garnacho-Montero J., Kesecioglu J., Lipman J., et al.  
 INTENSIVE CARE MEDICINE, vol.44, no.2, pp.189-196, 2018 (SCI-Expanded)
- LXIX. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines**  
 Mikulska M., Averbuch D., Tissot F., Cordonnier C., AKOVA M., Calandra T., Ceppi M., Bruzzi P., Viscoli C.  
 JOURNAL OF INFECTION, vol.76, no.1, pp.20-37, 2018 (SCI-Expanded)
- LXX. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study**  
 Harris P. N. A., Pezzani M. D., Gutierrez-Gutierrez B., Viale P., Hsueh P., Ruiz-Garbajosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., et al.  
 INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol.50, no.5, pp.664-672, 2017 (SCI-Expanded)
- LXXI. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort**  
 Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., Calbo E., Almirante B., Viale P., Oliver A., Pintado V., Gasch O., Martinez-Martinez L., Pitout J., et al.  
 CLINICAL INFECTIOUS DISEASES, vol.65, no.10, pp.1615-1623, 2017 (SCI-Expanded)
- LXXII. Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: A Clinical and Microbiological Study**  
 Tan Y., Zhou K., Tang X., Kudinha T., Wang L., Guo Z., AKOVA M., Zhuo C.  
 SCIENTIFIC REPORTS, vol.7, 2017 (SCI-Expanded)
- LXXIII. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological**

## **Patients with Neutropenia**

Gudiol C., Royo-Cebrecos C., Abdala E., AKOVA M., Alvarez R., Maestro-de la Calle G., Cano A., Cervera C., Clemente W. T., Martin-Davila P., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.61, no.8, 2017 (SCI-Expanded)

- LXXIV. **Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study**  
Gutierrez-Gutierrez B., Salamanca E., de Cueto M., Hsueh P., Viale P., Ramon Pano-Pardo J., Venditti M., Tumbarello M., Daikos G., Canton R., et al.  
LANCET INFECTIOUS DISEASES, vol.17, no.7, pp.726-734, 2017 (SCI-Expanded)
- LXXV. **IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS**  
Korucu B., Unal I., Pekcan M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., AKOVA M., ÜNAL S., ERDEM Y.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.32, 2017 (SCI-Expanded)
- LXXVI. **MP246IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS**  
KORUCU B., ÜNAL İ., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., AKOVA M., ÜNAL S.  
Nephrology Dialysis Transplantation, vol.32, pp.516-517, 2017 (SCI-Expanded)
- LXXVII. **An overview on severe infections in Europe**  
Dimopoulos G., AKOVA M.  
INTENSIVE CARE MEDICINE, vol.43, no.5, pp.686-689, 2017 (SCI-Expanded)
- LXXVIII. **Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study**  
Quan J., Li X., Chen Y., Jiang Y., Zhou Z., Zhang H., Sun L., Ruan Z., Feng Y., AKOVA M., et al.  
LANCET INFECTIOUS DISEASES, vol.17, no.4, pp.400-410, 2017 (SCI-Expanded)
- LXXIX. **Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- beta-lactamase-producing Enterobacteriaceae**  
Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., De Cueto M., Viale P., Venditti M., Hernandez-Torres A., Oliver A., Martinez-Martinez L., Calbo E., Pintado V., et al.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.72, no.3, pp.906-913, 2017 (SCI-Expanded)
- LXXX. **Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation**  
Alp Ş., AKOVA M.  
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, vol.9, 2017 (SCI-Expanded)
- LXXXI. **Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination**  
Blasi F., AKOVA M., Bonanni P., Dartois N., Sauty E., Webber C., Torres A.  
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.37, pp.13-18, 2017 (SCI-Expanded)
- LXXXII. **High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China**  
Quan J., Zhao D., Liu L., Chen Y., Zhou J., Jiang Y., Du X., Zhou Z., AKOVA M., Yu Y.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.72, no.1, pp.273-280, 2017 (SCI-Expanded)
- LXXXIII. **Antimicrobial Stewardship in Hematology Patients**  
AKOVA M.  
ANTIMICROBIAL STEWARDSHIP, vol.2, pp.205-217, 2017 (SCI-Expanded)
- LXXXIV. **Antimicrobial Stewardship in Turkey**  
Ergonul O., Can F., AKOVA M.  
ANTIMICROBIAL STEWARDSHIP, vol.2, pp.331-333, 2017 (SCI-Expanded)
- LXXXV. **Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?**  
METAN G., AKOVA M.  
CURRENT OPINION IN INFECTIOUS DISEASES, vol.29, no.6, pp.555-560, 2016 (SCI-Expanded)
- LXXXVI. **Evaluation of PNA-FISH Method for Direct Identification of Candida Species in Blood Culture Samples and Its Potential Impact on Guidance of Antifungal Therapy**



Dogan O, İNKAYA A. Ç., Gulmez D., UZUN Ö., AKOVA M., ARIKAN AKDAĞLI S.

MIKROBIYOLOJİ BULTENİ, vol.50, no.4, pp.580-589, 2016 (SCI-Expanded)

- LXXXVII. **A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae**  
Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh P, Viale P, Ramon Pano-Pardo J, Venditti M, Tumbarello M, Daikos G, Pintado V, et al.  
MAYO CLINIC PROCEEDINGS, vol.91, no.10, pp.1362-1371, 2016 (SCI-Expanded)
- LXXXVIII. **Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013**  
Zarakolu P, Eser O. K., Aladag E., Al-Zahrani I. A., Day K. M., Atmaca O., Boral B., Çakır B., Perry J. D., Akova M.  
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol.85, pp.466-470, 2016 (SCI-Expanded)
- LXXXIX. **A Multinational, Preregistered Cohort Study of beta-Lactam/beta-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae**  
Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, et al.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.60, no.7, pp.4159-4169, 2016 (SCI-Expanded)
- XC. **Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study**  
Gutierrez-Gutierrez B, Bonomo R. A., Carmeli Y., Paterson D. L., Almirante B., Martinez-Martinez L., Oliver A., Calbo E., Pena C., AKOVA M., et al.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.71, no.6, pp.1672-1680, 2016 (SCI-Expanded)
- XCI. **Epidemiology of antimicrobial resistance in bloodstream infections**  
AKOVA M.  
VIRULENCE, vol.7, no.3, pp.252-266, 2016 (SCI-Expanded)
- XCII. **Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality**  
ÇALIK BAŞARAN N., Karaagaoglu E., Hascelik G., DURUSU TANRIÖVER M., AKOVA M.  
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.4, pp.311-319, 2016 (SCI-Expanded)
- XCIII. **Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort**  
Abdul-Aziz M. H., Lipman J., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., Dulhunty J., Kaukonen K., Koulenti D., Martin C., et al.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.71, no.1, pp.196-207, 2016 (SCI-Expanded)
- XCIV. **Task force on management and prevention of Acinetobacter baumannii infections in the ICU**  
Garnacho-Montero J., Dimopoulos G., Poulakou G., AKOVA M., Miguel Cisneros J., De Waele J., Petrosillo N., Seifert H., Timsit J. F., Vila J., et al.  
INTENSIVE CARE MEDICINE, vol.41, no.12, pp.2057-2075, 2015 (SCI-Expanded)
- XCV. **Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease**  
Torres A., Blasi F., Dartois N., AKOVA M.  
THORAX, vol.70, no.10, pp.984-989, 2015 (SCI-Expanded)
- XCVI. **Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010**  
Alp S., ARIKAN-AKDAGLI S., GULMEZ D., ASCIOGLU S., UZUN Ö., AKOVA M.  
MYCOSES, vol.58, no.8, pp.498-505, 2015 (SCI-Expanded)
- XCVII. **Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey**  
Zarakolu P., Day K. M., SIDJABAT H. E., KAMOLVIT W., Lanyon C. V., Cummings S. P., PATERSON D. L., AKOVA M.,

Perry J. D.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.34, no.3, pp.519-525, 2015 (SCI-Expanded)

- XCVIII. **Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study**  
Sinnollareddy M. G., Roberts J. A., Lipman J., AKOVA M., Bassetti M., De Waele J. J., Kaukonen K., Koulenti D., Martin C., Montravers P., et al.  
CRITICAL CARE, vol.19, 2015 (SCI-Expanded)
- XCIX. **Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies**  
Kara O., Zarakolu P., AŞÇIOĞLU HAYRAN S., ETGÜL S., Uz B., BÜYÜKAŞIK Y., AKOVA M.  
INFECTIOUS DISEASES, vol.47, no.10, pp.686-693, 2015 (SCI-Expanded)
- C. **Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4)**  
Boga C., Bolaman Z., Cagirgan S., Karadogan I., ÖZCAN M. A., ÖZKALEMKAŞ F., Saba R., SÖNMEZ M., Senol E., AKAN H., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.100-117, 2015 (SCI-Expanded)
- CI. **Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006**  
Roca I., MOSQUEDA N., ALTUN B., ESPINAL P., AKOVA M., VILA J.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.69, no.12, pp.3437-3438, 2014 (SCI-Expanded)
- CII. **Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes Reply**  
Roberts J. A., Paul S. K., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., Kaukonen K., Koulenti D., Martin C., Montravers P., et al.  
CLINICAL INFECTIOUS DISEASES, vol.59, no.6, pp.907-908, 2014 (SCI-Expanded)
- CIII. **Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients**  
Mikulska M., Viscoli C., Orasch C., Livermore D. M., Averbuch D., Cordonnier C., AKOVA M.  
JOURNAL OF INFECTION, vol.68, no.4, pp.321-331, 2014 (SCI-Expanded)
- CIV. **DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current beta-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?**  
Roberts J. A., Paul S. K., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., Kaukonen K., Koulenti D., Martin C., Montravers P., et al.  
CLINICAL INFECTIOUS DISEASES, vol.58, no.8, pp.1072-1083, 2014 (SCI-Expanded)
- CV. **Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria**  
Petrosillo N., GIANNELLA M., ANTONELLI M., ANTONINI M., BARSIC B., BELANCIC L., Inkaya C. A., DE PASCALE G., GRILLI E., TUMBARELLO M., et al.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.58, no.2, pp.851-858, 2014 (SCI-Expanded)
- CVI. **Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study**  
Blot S., Koulenti D., AKOVA M., Bassetti M., De Waele J. J., Dimopoulos G., Kaukonen K., Martin C., Montravers P., Rello J., et al.  
CRITICAL CARE, vol.18, no.3, 2014 (SCI-Expanded)
- CVII. **European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia**  
Averbuch D., Orasch C., Cordonnier C., Livermore D. M., Mikulska M., Viscoli C., Gyssens I. C., Kern W. V., Klyasova G., Marchetti O., et al.  
HAEMATOLOGICA, vol.98, no.12, pp.1826-1835, 2013 (SCI-Expanded)
- CVIII. **Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant**

**recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)**

Averbuch D., Cordonnier C., Livermore D. M., Mikulska M., Orasch C., Viscoli C., Gyssens I. C., Kern W. V., Klyasova G., Marchetti O., et al.

HAEMATOLOGICA, vol.98, no.12, pp.1836-1847, 2013 (SCI-Expanded)

- CIX. **A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease**  
Ben-Ami R., Halaburda K., Klyasova G., Metan G., Torosian T., AKOVA M.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.68, pp.25-33, 2013 (SCI-Expanded)
- CX. **Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy-EORTC Infectious Diseases Group Trial XV**  
Kern W. V., Marchetti O., Drgona L., AKAN H., Aoun M., Akova M., de Bock R., Paesmans M., Viscoli C., Calandra T.  
JOURNAL OF CLINICAL ONCOLOGY, vol.31, no.9, pp.1149-1156, 2013 (SCI-Expanded)
- CXI. **Pneumonia Caused by Fusobacterium necrophorum Is Lemierre Syndrome Still Current**  
GÜLMEZ KIVANÇ D., ÖZYAVUZ ALP Ş., TOPELİ İSKİT A., AKOVA M., HASÇELİK A. G.  
Mikrobiyoloji Bulteni, vol.45, pp.729-734, 2011 (SCI-Expanded)
- CXII. **Low-level laser therapy supported teeth extractions of two patients receiving IV zoledronate**  
Kan B., Altay M. A., Tasar F., AKOVA M.  
LASERS IN MEDICAL SCIENCE, vol.26, no.5, pp.569-575, 2011 (SCI-Expanded)
- CXIII. **Comparative Evaluation of In Vitro Activities of Carbapenemes Against Gram-Negative Pathogens: Turkish Data of COMPACT Study**  
KORTEN V., Soyletir G., YALÇIN A. N., Ogunc D., Dokuzoguz B., Esener H., ULUSOY S., TÜNGER A., AYGEN B., Sumerkan B., et al.  
MIKROBIYOLOJİ BULTENİ, vol.45, no.2, pp.197-209, 2011 (SCI-Expanded)
- CXIV. **A novel fungal pathogen under the spotlight - Acremonium spp. associated fungaemia in an immunocompetent host**  
PÜRNAK T., Beyazit Y., Sahin G. O., Shorbagi A., AKOVA M.  
MYCOSES, vol.54, no.1, pp.78-80, 2011 (SCI-Expanded)
- CXV. **Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients**  
Pagano L., AKOVA M., Dimopoulos G., Herbrecht R., Drgona L., Blijlevens N.  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.66, 2011 (SCI-Expanded)
- CXVI. **The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study**  
Kucukardali Y., ÖNCÜL M. O., Cavuslu S., Danaci M., Calangu S., Erdem H., TOPÇU DURSUN A., Adibelli Z., AKOVA M., Karaali E. A., et al.  
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.12, no.1, pp.71-79, 2008 (SCI-Expanded)
- CXVII. **The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates-of Pseudomonas aeruginosa**  
ZARAKOLU P., METAN G., AYDIN N. G., ALTUN B., HASÇELİK A. G., AKOVA M.  
MIKROBIYOLOJİ BULTENİ, vol.41, no.3, pp.363-367, 2007 (SCI-Expanded)
- CXVIII. **Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues**  
Cornaglia G., Akova M., Amicosante G., Canton R., Cauda R., Docquier J., Edelstein M., Frere J., Fuzi M., Galleni M., et al.  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol.29, no.4, pp.380-388, 2007 (SCI-Expanded)
- CXIX. **Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt**  
Anaissie E. J., Segal B. H., Graybill J. R., Arndt C., Perfect J. R., Kleinberg M., Pappas P., Benjamin D., Rubin R., Aberg J. A., et al.  
CLINICAL INFECTIOUS DISEASES, vol.43, no.8, pp.1031-1039, 2006 (SCI-Expanded)
- CXX. **Emerging problem pathogens: A review of resistance patterns over time**  
Akova M.  
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.10, 2006 (SCI-Expanded)

- CXXI. **Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001)**  
Güven G., Uzun O., ÇAKIR B., Akova M., Unal S.  
SUPPORTIVE CARE IN CANCER, vol.14, no.1, pp.52-55, 2006 (SCI-Expanded)
- CXXII. **Fungal Infections in Neutropenic Patients**  
AKOVA M.  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol.26, 2005 (SCI-Expanded)
- CXXIII. **In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey**  
Kocagoz S., Akova M., Altun B., Gur D., Hascelik G.  
CLINICAL MICROBIOLOGY AND INFECTION, vol.8, no.4, pp.240-242, 2002 (SCI-Expanded)
- CXXIV. **Analysis of a mini-outbreak of methicillin-resistant Staphylococcus aureus in a surgical ward by using arbitrarily primed-polymerase chain reaction**  
CETINKAYA Y., KOCAGOZ S., HAYRAN M., Uzun O., Akova M., GURSU G., Unal S.  
JOURNAL OF CHEMOTHERAPY, vol.12, no.2, pp.138-144, 2000 (SCI-Expanded)
- CXXV. **Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis**  
GUR D., KOCAGOZ S., Akova M., Unal S.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.43, no.9, pp.2337, 1999 (SCI-Expanded)
- CXXVI. **Primary cutaneous aspergillosis in human immunodeficiency virus-infected patients: Two cases and review**  
ARIKAN S., Uzun O., CETINKAYA Y., KOCAGOZ S., Akova M., Unal S.  
CLINICAL INFECTIOUS DISEASES, vol.27, no.3, pp.641-643, 1998 (SCI-Expanded)
- CXXVII. **Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis**  
ARIKAN S., AKOVA M., HAYRAN M., OZDEMIR O., ERMAN M., GUR D., Unal S.  
CLINICAL INFECTIOUS DISEASES, vol.26, no.4, pp.903-908, 1998 (SCI-Expanded)
- CXXVIII. **A randomized multicenter comparative study of cefepime and ceftazidime in combination with amikacin in the treatment of patients with fever and neutropenia**  
ERMAN M., Akan H., KORTEN V., Ferhanoğlu B., UZUN Ö., ÜNAL S., AKOVA M.  
Clinical Infectious Diseases, vol.25, no.2, pp.463, 1997 (SCI-Expanded)
- CXXIX. **Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients**  
ARIKAN S., Gur D., AKOVA M.  
MYCOSES, vol.40, pp.291-296, 1997 (SCI-Expanded)
- CXXX. **Treatment of enteric fever with pefloxacin for 7 days versus 5 days: A randomized clinical trial**  
Unal S., HAYRAN M., TUNCER S., GUR D., Uzun O., Akova M., AKALIN H.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.40, no.12, pp.2898-2900, 1996 (SCI-Expanded)
- CXXXI. **Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections**  
Akova M., Özcebe O. İ., Gullu I., Unal S., GUR D., AKALIN S., TOKGOZOGLU M., TELATAR F., AKALIN H.  
JOURNAL OF CHEMOTHERAPY, vol.8, no.4, pp.284-289, 1996 (SCI-Expanded)
- CXXXII. **QUINOLONES IN TREATMENT OF HUMAN BRUCELLOSIS - COMPARATIVE TRIAL OF OFLOXACIN-RIFAMPIN VERSUS DOXYCYCLINE-RIFAMPIN**  
AKOVA M., UZUN O., AKALIN H., HAYRAN M., UNAL S., GUR D.  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.37, no.9, pp.1831-1834, 1993 (SCI-Expanded)

## Articles Published in Other Journals

- I. Common Problems and Solutions in the Management of Resistant Gram-Negative Bacterial

## **Infections: Expert Opinion on Clinical Practice**

Suemer S., Azap o. K. U. R. T., Ayguen G., AKALIN E. H., AKOVA M., KÖKSAL I.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJİ DERGİSİ, vol.29, no.1, pp.1-24, 2024 (ESCI)

- II. **Current practice of screening and antimicrobial prophylaxis to prevent Gram-negative bacterial infection in high-risk haematology patients: results from a pan-European survey**  
Stemler J., Gavriilaki E., Hlukhareva O., Khanna N., Neofytos D., AKOVA M., Pagano L., Cisneros J., Cornely O. A., Salmanton-Garcia J.  
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2024 (ESCI)
- III. **"Good" News from IDCM and Thanks to All Who Contributed**  
AKOVA M.  
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, no.4, pp.266, 2023 (ESCI)
- IV. **Voriconazole Therapeutic Drug Level Monitoring: A University Hospital Experience**  
KARA E., BAKIR EKİNCİ P., METAN G., EKİNCİOĞLU A., PINAR A., AKOVA M., UZUN Ö.  
FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJİ DERGİSİ, vol.27, no.1, pp.183-188, 2022 (ESCI)
- V. **Pulmonary nocardiosis caused by Nocardia abscessus mimicking pulmonary thromboembolism in a patient with atypical anti-glomerular basement membrane glomerulonephritis**  
Ismayilov R., Koray N., İNAL N., TELLİ DİZMAN G., HAZIROLAN G., DURUSU TANRIÖVER M., AKOVA M.  
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.2, pp.237-241, 2021 (ESCI)
- VI. **Effects of Cytochrome p450 (CYP) 2C19 Genetic Polymorphisms on Voriconazole Serum Levels: A Report of Two Cases**  
TAŞ Z., KARA E., DEĞER O., İspirli M., METAN G., BABAOĞLU M. Ö., AKOVA M.  
Mediterranean Journal of Infection, Microbes and Antimicrobials, vol.10, 2021 (Scopus)
- VII. **Splenic Actinomycosis in a Patient with Chronic Granulomatous Disease: A Case Report and Review of the Literature**  
AYAZ Ç. M., Hasanlı N., Demirci Duarte S., HAZIROLAN G., İNKAYA A. Ç., ÇİFTÇİ T. T., AKOVA M.  
Infectious Diseases and Clinical Microbiology, vol.1, no.3, pp.158-164, 2019 (Peer-Reviewed Journal)
- VIII. **Acinetobacter baumannii Infection and Colonization in the Intensive Care Unit: Risk Factors, Transmission Routes, and Transmission Dynamics**  
KIZILARSLANOĞLU M. C., Ergonul O., Cetinkaya-Sardan Y., AKOVA M.  
KLİMİK JOURNAL, vol.31, no.1, pp.20-29, 2018 (ESCI)
- IX. **The risk of pneumococcal disease in lung diseases and the importance of adult vaccination in the treatment of adult pneumococcal disease in lung diseases**  
SAYINER A., MİRİCİ A., ÇİLLİ A., Uzaslan E., AKOVA M., ÖZHAN M. H., KILINÇ O.  
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, vol.62, no.2, pp.154-159, 2014 (ESCI)
- X. **Management of febrile neutropenia in the era of bacterial resistance**  
ÖZYAVUZ ALP Ş., AKOVA M.  
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, vol.1, no.1, pp.37-43, 2013 (ESCI)
- XI. **TİGESİKLİN**  
ÇALIK BAŞARAN N., AKOVA M.  
ANKEM Dergisi, vol.21, no.2, pp.29-33, 2007 (Peer-Reviewed Journal)
- XII. **Çeşitli Hastanelerde İzole Edilen Stafilokok Suşlarının Fusidik Asit ve Sık Kullanılan Diğer Antibiyotiklere Duyarlılıkları**  
ALTUN B., KOCAGÖZ A. S., HASÇELİK A. G., UZUN Ö., AKOVA M., ÜNAL S.  
Türk Mikrobiyoloji Cemiyeti Dergisi, vol.33, pp.8-11, 2003 (Peer-Reviewed Journal)
- XIII. **Native valve endocarditis with persistent embolization due to Neisseria mucosa [4]**  
Tuncer S., HAYRAN K. M., Akan O., Gur D., AKOVA M., ÜNAL S.  
Clinical Microbiology and Infection, vol.3, no.1, pp.137-139, 1997 (Scopus)
- XIV. **Efficacy of a three day course of azithromycin in the treatment of community acquired pneumococcal pneumonia Preliminary report**  
UZUN Ö., Hayran M., AKOVA M., Akalın E.  
Journal of Chemotherapy, vol.6, no.1, pp.53-57, 1994 (Scopus)

- XV. **Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole**  
AKOVA M., Akalin H., UZUN Ö., GÜR D.  
European Journal of Clinical Microbiology & Infectious Diseases, vol.10, no.7, pp.598-599, 1991 (Scopus)

## Books & Book Chapters

- I. **Araştırma A. SARS-CoV-2 Faz III Aşı Çalışmaları**  
Dikçınar Yücesoy S. N., Özusta Ş., İNKAYA A. Ç., DURUSU TANRIÖVER M., AKOVA M., ÜNAL S.  
in: Covid-19 Pandemi Raporu (20 Mart-20 Kasım 2020), Topeli İskit A, Durusu Tanrıöver M, Uzun Ö, Editor, Uzerler Matbaası, Ankara, pp.256-266, 2021
- II. **Kulak burun boğaz, baş boyun cerrahisinde antibiyotik kullanımı**  
ZARAKOLU KÖŞKER I. P., AKOVA M.  
in: Kulak Burun Boğaz hastalıkları ve Baş Boyun Cerrahisi, Can Koç, Editor, Güneş Tıp, Ankara, pp.33-37, 2019
- III. **Enfektif Endokardit, Miyokardit, Perikardit**  
İNKAYA A. Ç., AKOVA M.  
in: Enfeksiyon Hastalıkları ve Mikrobiyolojisi, Topçu Ayşe Willke, Söyletir Güner, Doğanay Mehmet, Editor, Nobel Tıp Kitabevleri, İstanbul, pp.951-969, 2017
- IV. **Antibiyotik Tedavisinin Esasları**  
İNKAYA A. Ç., AKOVA M.  
in: Yaşlılıkta İnfeksiyonlar, Köse Şükran, Yalçın Ata Nevzat, Erbay Rıza Hakan, Editor, Bulaşıcı Hastalıkları Önleme Derneği Yayınları, İzmir, pp.67-73, 2013
- V. **İNVAZİV ASPERGİLLOZİS**  
ÇALIK BAŞARAN N., AKOVA M.  
in: FEBRİL NÖTROPENİ, MURAT AKOVA, HAMDİ AKAN, Editor, BİLİMSEL TIP YAYINEVİ, Ankara, pp.431-449, 2010
- VI. **NÖTROPENİK HASTALARDA İNFEKSİYONLAR**  
ÇALIK BAŞARAN N., AKOVA M.  
in: ENFEKSİYON HASTALIKLARI VE MİKROBİYOLOJİSİ, AYŞE WİLKE TOPÇU, GÜNER SÖYLETİR, MEHMET DOĞANAY, Editor, NOBEL TIP KİTABEVİ, İstanbul, pp.641-650, 2008
- VII. **YETİŞKİNLERDE İNFLUENZA AŞILAMASI**  
ÇALIK BAŞARAN N., AKOVA M.  
in: GRİP ÖNLEMLER VE TEDAVİ, MEHMET CEYHAN, Editor, MEDYA TOWERTANITIM VE YAYINCILIK HİZMETLERİ, İstanbul, pp.47-62, 2007

## Refereed Congress / Symposium Publications in Proceedings

- I. **EARLY CESSATION OF EMPIRICAL ANTIBACTERIAL THERAPY IN HIGH-RISK FEBRILE NEUTROPENIC PATIENTS WITH FEVER OF UNKNOWN ORIGIN (FUO)**  
KORUCU B., İNKAYA A. Ç., ERBİL A., OKAY M., AŞÇIOĞLU S., TOKUÇOĞLU ALTUNAY H., AKOVA M.  
20TH SYMPOSIUM ON INFECTIONS IN THE IMMUNOCOMPROMISED HOST, ATİNA, Greece, 17 - 19 July 2019, pp.76
- II. **Mixed fungemia within 18-years in a university hospital and antifungal susceptibility profiles of the isolates**  
GÜLMEZ KIVANÇ D., ÖZYAVUZ ALP Ş., GÜRSOY G., AYAZ Ç. M., DOĞAN Ö., ARIKAN AKDAĞLI S., AKOVA M.  
Balkan Fungus 2018 First Balkan Conference on Medical Mycology and Mycotoxicology, Temeşvar, Romania, 13 - 15 September 2018, vol.26, pp.70-71
- III. **Compliance to the guideline of diagnostic tests in febrile neutropenic patients at a Turkish university hospital'**  
ZARAKOLU KÖŞKER I. P., AKOVA M., BÜYÜKAŞIK Y., DURUSU TANRIÖVER M., DİZDAR Ö., METAN G., baştuğ z.  
20th Symposium on Infections in the immunocompromised host, Atina, Greece, 17 - 19 June 2018
- IV. **Impact of effective antibiopic therapy on mortality in patients with XDR Acinetobacter baumannii**

**bloodstream infections**

ZARAKOLU KÖŞKER I. P., AKOVA M., ESER Ö., Özdede M., METAN G.

20th Symposium on Infections in the immunocompromised host, Atina, Greece, 17 - 19 June 2018

- V. **Concomitant Herpes Simplex and Cytomegalovirus Reactivations in a Mycosis Fungoides Patient under Romidepsin Treatment: A Case Report**  
İNKAYA A. Ç., DOĞAN GÜNAYDIN S., ÖZYAVUZ ALP Ş., AKOVA M.  
20th ICHS Symposium on Infections in the Immunocompromised Host, 17 - 19 June 2018
- VI. **Evaluation of 2 commercial assays for the rapid confirmation of OXA-48 carbapenemases from Klebsiella pneumoniae isolates', P3, p.72, Athens, Greece, 2018.**  
ZARAKOLU KÖŞKER I. P., AKOVA M., Perry J., ASLAN A. T.  
20th Symposium on Infections in the immunocompromised host, Atina, Greece, 17 - 19 June 2018
- VII. **SALMONELLA GRUP D'NİN NEDEN OLDUĞU SEPTİK ARTRİT OLGUSU**  
KARDAŞ R. C., BIÇAKCIGİL A., ERDUT A., ÇİÇEK M., LİSTE Ü., ALTUN B., İNKAYA A. Ç., SANCAK B., AKOVA M.  
4 ULUSAL KLİNİK MİKROBİYOLOJİ KONGRESİ, Turkey, 8 - 12 November 2017
- VIII. **Fungemia due to rare yeasts and antifungal susceptibility profiles in a tertiary care university center**  
ÖZYAVUZ ALP Ş., GÜLMEZ KIVANÇ D., AYAZ Ç. M., ARIKAN AKDAĞLI S., AKOVA M.  
8th Trends in Medical Mycology, 6 - 09 October 2017
- IX. **In vivo evaluation of protective effect of hydration with sodium chloride versus urine**  
KORUCU B., ÜNAL I., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., HAYRAN K. M., demir m. t., İNKAYA A. Ç., AKOVA M., ÜNAL S., et al.  
54th era-edta congress, 3 - 06 June 2017
- X. **IN VIVO EVALUATION OF PROTECTIVE EFFECT OF HYDRATION WITH SODIUM CHLORIDE VERSUS URINE ALKALINISATION ON COLISTIN INDUCED NEPHROTOXICITY IN RATS**  
KORUCU B., ÜNAL I., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., İNKAYA A. Ç., AKOVA M., ÜNAL S., ERDEM Y.  
54th ERA-EDTA CONGRESS, Madrid, Spain, 3 - 06 June 2017
- XI. **Can urine alkalinisation be a treatment option on colistin induced nephrotoxicity: an ultrastructural and histochemical study on rats**  
KORUCU B., ÜNAL I., PEKCAN M., ÇETİNKAYA M. A., KAYMAZ F. F., HAYRAN K. M., İNKAYA A. Ç., AKOVA M., ÜNAL S., ERDEM Y.  
15th International Congress of Histochemistry and Cytochemistry (ICHC 2017) in Antalya, 18 - 21 May 2017
- XII. **The changing epidemiology of candidaemia in a tertiary care university centre. P0959**  
ÖZYAVUZ ALP Ş., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., AKOVA M.  
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Viyana, Austria, 22 - 25 April 2017
- XIII. **Listeria rhomboensefalit Farklı yüzler farklı tarzlar**  
AKOVA M., GÖÇMEN R., KARLI OĞUZ H. K., MUT AŞKUN M., TOPÇUOĞLU M. A., ÜNAL ÇEVİK I., İNKAYA A. Ç., TUNCER M. A.  
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- XIV. **Levofloksasin profilaksisi alan hematolojik kanserli nötropenik hastalarda kinolon dirençli Escherichia coli sürveyansı**  
ETGÜL S., ZARAKOLU KÖŞKER I. P., ESER Ö., KARA Ö., BÜYÜKAŞIK Y., Akova M.  
3. Ulusal Klinik Mikrobiyoloji Uzmanlık Derneği Kongresi, Turkey, 18 - 22 November 2015
- XV. **Etgül S P Zarakolu Ö K Eser Ö Kara Y Büyükaşık M Akova Impact of Levofloxacin Prophylaxis LP in Acute Leukaemia AL Patients with Neutropenia in a High Quinolone Resistance Setting Proc p P1207 Copenhagen Denmark 2015**  
ETGÜL S., ZARAKOLU KÖŞKER I. P., AKOVA M., Kara Ö.  
24th European Congress of Clinical Microbiology and Infectious Diseases, 25 - 28 April 2015
- XVI. **Kan kültürlerinden izole edilen Candida türlerinin PNA FISH yöntemiyle hızlı tanımlanmasının konvansiyonel tanımlama yöntemleriyle uyum ve antifungal tedavinin yönlendirilmesine olası etki yönünden değerlendirilmesi**  
DOĞAN AYÇIK Ö., İNKAYA A. Ç., GÜLMEZ KIVANÇ D., UZUN Ö., AKOVA M., ARIKAN AKDAĞLI S.

Febril Nötropeni Klavuz Toplantısı, Ankara, Turkey, 29 - 30 March 2014

- XVII. **Mart 2006 Ocak 2013 yılları arasında Hacettepe Üniversitesi Erişkin Hastanesi nde küf mantarı üremesi olan hastaların dağılımı**  
HA Y., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., DOĞAN AYÇIK Ö., AKOVA M.  
10. Febril Nötropeni Simpozyumu, Ankara, Turkey, 17 - 19 May 2013
- XVIII. **Epidemiology of Candida bloodstream infections and antifungal susceptibility profiles 10 year experience with 381 candidaemia episodes in a tertiary care university centre**  
ÖZYAVUZ ALP Ş., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., AŞÇIOĞLU HAYRAN S., UZUN Ö., AKOVA M.  
European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Londrina, United Kingdom, 31 March - 03 April 2012
- XIX. **A retrospective study comparing cefoperazone sulbactam with piperacillin tazobactam as empirical therapy for febrile neutropenia in adults with hematological disorders**  
bitik b., ÖZYAVUZ ALP Ş., ÇALIK BAŞARAN N., AKOVA M., UZUN Ö., ÜNAL S.  
8th Congress of The European Federation of Internal Medicine, İstanbul, Turkey, 27 - 30 May 2009, vol.20, pp.225
- XX. **HEMATOLOJİK MALİGNİTELİ HASTALARDA KAN DOLAŞIMI İNFEKSİYONLARININ SIKLIĞI VE ETKENLERİN DAĞILIMI HACETTEPE DE DEĞİŞİMİ**  
ÇALIK BAŞARAN N., ÖZVEREN A., AKOVA M.  
8. FEBRİL NÖTROPENİ SEMPOZYUMU, Ankara, Turkey, 21 - 24 February 2008
- XXI. **KANSER HASTALARINDA FUNGEMİ GÖRÜLME SIKLIĞI HACETTEPE DENEYİMİ**  
ÖZVEREN A., ÇALIK BAŞARAN N., AKOVA M.  
8. FEBRİL NÖTROPENİ SEMPOZYUMU, Ankara, Turkey, 21 - 24 February 2008, pp.183
- XXII. **EPIDEMIOLOGY OF BACTERIAL INFECTIONS AND RISK FACTORS FOR MORTALITY IN CANCER PATIENTS**  
ÇALIK BAŞARAN N., KARAAĞAOĞLU A. E., HASÇELİK A. G., AKOVA M.  
INTERSCIENCE CONFERENCE ON ANTİMİCROBİAL AGENTS AND CHEMOTHERAPY, Washington, Kiribati, 16 - 19 December 2005
- XXIII. **An open study of clarithromycin in the treatment of pneumonia due to Streptococcus pneumoniae**  
HAYRAN M., Erman M., GUR D., Akova M., Unal S.  
3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portugal, 24 - 26 January 1996, vol.21, pp.429-431

## Supported Projects

AKOVA M., DAĞ O., SANCAK B., SAİN GÜVEN G., ASLAN A. T., Project Supported by Higher Education Institutions, Karbapenem Dirençli Klebsiella Pneumoniae Bakteremisi Olan Hastalarda Mortalite Riskini Artıran Faktörlerinin Belirlenmesi ve Kullanılan Antibiyotik Tedavilerinin Mortalite ve Klinik Başarı Üzerine Etkilerinin Araştırılması, 2020 - 2022

ÖZSÜREKÇİ Y., CEYHAN M., AKOVA M., TOPELİ İSKİT A., CENGİZ A. B., ALP A., ARASLI M., HALAÇLI B., AYKAÇ K., CURA YAYLA B., et al., Project Supported by Higher Education Institutions, COVID19 Pozitif Çocuklarda Erişkinlere Kıyasla İy Klinik Seyir Sitokin ve Kemokin Cevaplarıyla Açıklanabilir mi?, 2020 - 2020

## Metrics

Publication: 186

Citation (WoS): 3428

Citation (Scopus): 3800

H-Index (WoS): 29

H-Index (Scopus): 30



## **Non Academic Experience**

Hacettepe Üniversitesi Tıp Fakültesi

SSK bayrampaşa Dispanseri

Adalet Bakanlığı Çankırı Kapalı Cezaevi Tabipliği